Tror ikke det er noe annet enn at det er kvartalsresultater på torsdag og folk ikke har de største forventningene.
1 Like
Det här är manipulation av aktien. Någon vill komma åt billigare aktier.
3 av 4 research centers rekrutterer til ovarian/coloreactal studiet hvor Targovax leverer oncos til Ludwig Institute.
Kjenner denne studien varmer mitt hjerte.
1 Like
Hva tenker du/dere om forventningene?
Det er vel ventet kun en readout iløpet av året, ellers er vel det meste av nyheter mer inn i 1H2019. Tenker det er lite som forventes negativt, om det er så tilfelle er jeg interessert å høre hvorfor.
Ser heller ikke de positive drivende nyhetene på dette tidspunkt, men dette er jo allerede kjent.
Hva er det som forventes av nyheter?
Hvordan ligger de ann med proof of concept i Oncos-studien?
Det tekniske ser nitrist ut. Melding kan selvfølgelig sende den opp, men jeg hadde ikke kjøpt meg inn uten å være forberedt/ha en klar plan for videre nedgang 
Skal sies at jeg selv har ordrer på 10-tallet da 
Når man minst venter det… (Ønsketenkning) 
flere som fikk noen fine kjøp nå 
3 Likes
" In an ongoing phase I trial in
advanced melanoma we expect important proof of concept data in the treatment of checkpoint
inhibitor refractory patients.
- Upcoming milestones
1H2018: TG01 phase I/II trial in resected pancreatic cancer
– survival data
2H2018: ONCOS-102 phase I trial in checkpoint inhibitor
refractory melanoma
– interim data
Fra Q1.
Hvis det er denne ONCOS studien du (melanoma) tenker på , så er det den vi venter info på.
Hittil kjente nyheter er vel: …announces encouraging results from its phase I/II trial of ONCOS-102 in mesothelioma, in combination with standard of care chemotherapy, in which clinical responses were observed in three out of the first six patients. – fra 02.mai safety mesothelioma.
Fra press release angående første pasient i SOTIO studiet lyder det:
ONCOS-102’s lead indication is mesothelioma where the virus is currently being developed in a phase II trial. A second trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients.
Slik jeg forstår det er dette vi vet pdd. For å svare på spørsmålet ditt, så venter vi på proof of concept enda på mesothelioma, men har safety.
Proof of concept i melanoma forventes, men de har demonstrert immunaktivering ref pdf til Savepig ovenfor.
Syns faktisk den var veldig oversiktlig, og fin.
Gjerne rett meg om noe er feil. Noe uoversiktlig fra Targovax når man prøver å skille de forskjellige studiene syns jeg, men mulig noen her sitter med god oversikt.
Sitter og leser Q1 nå. Jeg har ganske stor tro på Oncos-102, kanskje særlig studien med Keytruda i Melanoma og med pem/cis i Mesothelioma. Forventer bedring i kursen hvis Melanoma readout gir positive signaler!
Siden Arctic analysen kom så har vel kun ONCOS vært vektlagt av verdi, selv om den falt til 10 tallet når de annonserte TG på pause. Utrolig nok.
Enig med deg @Fornybar , spesielt melanoma virker å gjøre det bra. Men virker som de har veldig troa selv også på mesothelioma studien.
Også spent på SOTIO samarbeidet. Ingenting som tilsier at dette skal bli bra enda. Men om de klarer å vise til reaksjoner her åpner det opp for et relativt stort marked i prostatcancer.
1 Like
Summer topp 10 og other shareholders, så mangler det 6,1 % av aksjene.
What gives?
Vilket köptillfälle. Hoppas att alla har lastat upp. Tyvärr kan jag inte köpa fler. 
Ser ut som om det kanskje er bl.a Meyerløkka som sitter og trader denne ned. Ellers er det jo ingenting som skjer. Bare tull. Dere som ikke måtte punge ut til kemnereren denne uka får kjøpe litt, da
1 Like
Takk for listen, Inkog. Gull verdt
Kanskje vi får vite hva som skjer med TG-01 i morgen? Soug sa jo i podcast etter meldingen at de kommer til å bruke de neste ukene og månedene på å diskutere hvordan de skal ta TG-01 videre. Nå har det jo gått godt over to måneder siden han sa det. Hvem veit, kanskje det kommer en veldig positiv overraskelse i morgen. Det sagt så har de guidet det til høst på meldingen. Men er det en ting som er sikkert i biotek er at nyheter kan komme når som helst uavhengig av guiding.
Targovax ASA: Second quarter and first half year 2018 results
Oslo, Norway, 23 August 2018 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard to treat solid
tumors, today announces its second quarter and first half year 2018 results.A meeting for investors, analysts and press will take place in Oslo today at
10:00 CET (details below).
HIGHLIGHTS FOR THE SECOND QUARTER AND FIRST HALF YEAR 2018· In January, Targovax announced that ONCOS-102 generated immune activation at
both the systemic and lesional levels in checkpoint inhibitor (CPI) refractory
melanoma in four out of the first four patients treated· In February, Targovax announced that the safety lead-in part of its ONCOS
-102 trial in unresectable, malignant, pleural mesothelioma was completed
without any safety concerns, and that ONCOS-102 generates early immune
activation in treated patients· In May, an early signal of efficacy was reported from the ONCOS-102 phase
I/II trial in mesothelioma, with activity observed in three out of six patients
in the safety lead-in cohort. The trial has now entered the randomized phase II
part, enrolling 24 more patients· In May, survival data was reported from the 32-patient phase I/II clinical
trial evaluating TG01 in resected pancreatic cancer in combination with
gemcitabine chemotherapy. Median overall survival for the patients vaccinated
with TG01 was 33.4 months, compared with 27.6 months for gemcitabine alone
reported in the ESPAC4 trial· In June, the Company updated its business strategy, strengthening the
development focus on the ONCOS oncolytic virus program, with ONCOS-102 as the
lead product candidate· In June, Targovax was granted a product patent in the EU for TG02, the 2nd
generation product from the mutant-RAS neoantigen vaccine platform· In April, Dr. Catherine A. Wheeler was elected as a new member of the Board
of DirectorsPOST-PERIOD HIGHLIGHTS
· In July, Ludwig Cancer Research and CRI announced the completion of the
safety evaluation for the first dose cohort in the phase I/II trial of ONCOS-102
in combination with MedImmune’s checkpoint inhibitor Imfinzi® (durvalumab)· In July, Targovax and SOTIO announced that the first patient was dosed in
the phase I/II combination trial of ONCOS-102 with DCVAC, a dendritic cell
immune-therapyØystein Soug, CEO said: “It has been an exciting first half of 2018 for the
oncolytic virus field. Clinical data, both from Targovax and others, have
reinforced the scientific foundation of oncolytic viruses as an important class
of immune activators. Oncolytic virus therapies have been further highlighted by
recent deal activity in the space. Therefore, it is natural for Targovax to
strengthen its efforts on the ONCOS program. We look forward to several upcoming
data read-outs within the next year. We continue to see potential in the TG neo
-antigen cancer vaccine to treat mutant RAS cancers, and are working closely
with our scientific advisors to devise an updated strategy for how to best
create value for both patients and shareholders. We aim to announce a revised
development plan for the TG program during the autumn.”Presentation
The presentation will take place at 10:00 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 OsloThe presentation will also be webcast live and can be accessed through
www.targovax.com (http://webtv.hegnar.no/presentation.php?webcastId=92033021)..)Reporting material
Targovax second quarter and first half 2018
report (http://mb.cision.com/Public/17093/2598847/b6e92fb072f0f891.pdf)Targovax second quarter and first half 2018
presentation (http://mb.cision.com/Public/17093/2598847/ba46e09249a958d0.pdf)The quarterly report and presentation are also available at the website
www.targovax.com (http://www.targovax.com/Investors/financials/Quarterly
-Reports/default.aspx).For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected]
About TargovaxActivating the patient’s immune system to fight cance
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard to treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It is used as a therapeutic cancer vaccine and has
been shown to activate the immune system to generate tumor-specific immune
responses. In phase I trials, ONCOS-102 induced both local and systemic innate
and adaptive immune activation, which has been associated with clinical benefit.
ONCOS-102’s lead indication is mesothelioma, where the virus is currently being
tested in a randomized phase II trial, with a phase Ib safety lead-in cohort.
Another trial, in advanced melanoma, is expected to produce important proof of
concept data for checkpoint inhibitor refractory patients within the next 6-12
months.Targovax is also developing a neo-antigen cancer vaccine targeting tumors that
express mutated forms of RAS - mutations known to drive cancer. The TG vaccine
program has shown a signal of efficacy in a 32-patient trial with TG01 in
resected pancreatic cancer. A next generation product candidate, TG02 is
currently tested as monotherapy and will also be tested in combination with
Keytruda® (an anti-PD1 Check point inEkstern link: http://www.newsweb.no/index.jsp?messageId=457867
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180823.OBI.20180823S8
2 Likes
Noen av dere som får lyd og bilde fra webcasten?